Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

Immunity

Volumn 45, Issue 5, 2016, Pages 1108-1121

  Huang, Jinghe ^a   Kang, Byong H ^a   Ishida, Elise ^a   Zhou, Tongqing ^a   Griesman, Trevor ^a   Sheng, Zizhang ^b   Wu, Fan ^a   Doria Rose, Nicole A ^a   Zhang, Baoshan ^a   McKee, Krisha ^a   O'Dell, Sijy ^a   Chuang, Gwo Yu ^a   Druz, Aliaksandr ^a   Georgiev, Ivelin S ^c,d,e   Schramm, Chaim A ^b   Zheng, Anqi ^a   Joyce, M Gordon ^a   Asokan, Mangaiarkarasi ^a   Ransier, Amy ^a   Darko, Sam ^a   Migueles, Stephen A ^a   Bailer, Robert T ^a   Louder, Mark K ^a   Alam, S Munir ^d   Parks, Robert ^d   Kelsoe, Garnett ^d   Von Holle, Tarra ^d   Haynes, Barton F ^d   Douek, Daniel C ^a   Hirsch, Vanessa ^a   Seaman, Michael S ^e   Shapiro, Lawrence ^a,b   Mascola, John R ^a   Kwong, Peter D ^a   Connors, Mark ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antibody; CD4 binding site; envelope; HIV; immunotherapy; neutralizing; prophylaxis; resistance; structure; vaccine

Indexed keywords

12A 21; B LYMPHOCYTE RECEPTOR; CD4 ANTIGEN; GLYCAN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; N 6; UNCLASSIFIED DRUG; VRC 01; VRC 27; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; DRUG PROTEIN BINDING; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEMORY CELL; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; CD4+ T LYMPHOCYTE; CELL SEPARATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84999836139     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.10.027     Document Type: Article

References (38)

1. Burton, D.R., Mascola, J.R., Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16 (2015), 571–576.
2. Crooks, E.T., Tong, T., Chakrabarti, B., Narayan, K., Georgiev, I.S., Menis, S., Huang, X., Kulp, D., Osawa, K., Muranaka, J., et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathog., 11, 2015, e1004932.
3. Das, S.R., Puigbò, P., Hensley, S.E., Hurt, D.E., Bennink, J.R., Yewdell, J.W., Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog., 6, 2010, e1001211.
4. Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P. Jr., Klein, F., Gao, H., Gnanapragasam, P.N., Abadir, A., Seaman, M.S., Nussenzweig, M.C., Bjorkman, P.J., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334 (2011), 1289–1293.
5. Diskin, R., Klein, F., Horwitz, J.A., Halper-Stromberg, A., Sather, D.N., Marcovecchio, P.M., Lee, T., West, A.P. Jr., Gao, H., Seaman, M.S., et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210 (2013), 1235–1249.
6. Doria-Rose, N.A., Klein, R.M., Daniels, M.G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S.A., Wyatt, R.T., Korber, B.T., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84 (2010), 1631–1636.
7. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
8. Gao, F., Bonsignori, M., Liao, H.X., Kumar, A., Xia, S.M., Lu, X., Cai, F., Hwang, K.K., Song, H., Zhou, T., et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158 (2014), 481–491.
9. Garces, F., Lee, J.H., de Val, N., de la Pena, A.T., Kong, L., Puchades, C., Hua, Y., Stanfield, R.L., Burton, D.R., Moore, J.P., et al. Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity 43 (2015), 1053–1063.
10. Georgiev, I.S., Doria-Rose, N.A., Zhou, T., Kwon, Y.D., Staupe, R.P., Moquin, S., Chuang, G.Y., Louder, M.K., Schmidt, S.D., Altae-Tran, H.R., et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340 (2013), 751–756.
11. Haynes, B.F., New approaches to HIV vaccine development. Curr. Opin. Immunol. 35 (2015), 39–47.
12. Helle, F., Vieyres, G., Elkrief, L., Popescu, C.I., Wychowski, C., Descamps, V., Castelain, S., Roingeard, P., Duverlie, G., Dubuisson, J., Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 84 (2010), 11905–11915.
13. Huang, J., Doria-Rose, N.A., Longo, N.S., Laub, L., Lin, C.L., Turk, E., Kang, B.H., Migueles, S.A., Bailer, R.T., Mascola, J.R., Connors, M., Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 8 (2013), 1907–1915.
14. Klein, F., Nogueira, L., Nishimura, Y., Phad, G., West, A.P. Jr., Halper-Stromberg, A., Horwitz, J.A., Gazumyan, A., Liu, C., Eisenreich, T.R., et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211 (2014), 2361–2372.
15. Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005), 10108–10125.
16. Li, Y., O'Dell, S., Walker, L.M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S.D., McKee, K., Louder, M.K., Ledgerwood, J.E., et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85 (2011), 8954–8967.
17. Liu, M., Yang, G., Wiehe, K., Nicely, N.I., Vandergrift, N.A., Rountree, W., Bonsignori, M., Alam, S.M., Gao, J., Haynes, B.F., Kelsoe, G., Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 89 (2015), 784–798.
18. Lynch, R.M., Wong, P., Tran, L., O'Dell, S., Nason, M.C., Li, Y., Wu, X., Mascola, J.R., HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89 (2015), 4201–4213.
19. MacLeod, D.T., Choi, N.M., Briney, B., Garces, F., Ver, L.S., Landais, E., Murrell, B., Wrin, T., Kilembe, W., Liang, C.H., et al., IAVI Protocol C Investigators & The IAVI African HIV Research Network. Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity 44 (2016), 1215–1226.
20. Moore, P.L., Gray, E.S., Wibmer, C.K., Bhiman, J.N., Nonyane, M., Sheward, D.J., Hermanus, T., Bajimaya, S., Tumba, N.L., Abrahams, M.R., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18 (2012), 1688–1692.
21. Pappas, L., Foglierini, M., Piccoli, L., Kallewaard, N.L., Turrini, F., Silacci, C., Fernandez-Rodriguez, B., Agatic, G., Giacchetto-Sasselli, I., Pellicciotta, G., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516 (2014), 418–422.
22. Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100 (2003), 4144–4149.
23. Rudicell, R.S., Kwon, Y.D., Ko, S.Y., Pegu, A., Louder, M.K., Georgiev, I.S., Wu, X., Zhu, J., Boyington, J.C., Chen, X., et al., NISC Comparative Sequencing Program. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88 (2014), 12669–12682.
24. Rusert, P., Kouyos, R.D., Kadelka, C., Ebner, H., Schanz, M., Huber, M., Braun, D.L., Hozé, N., Scherrer, A., Magnus, C., et al., Swiss HIV Cohort Study. Determinants of HIV-1 broadly neutralizing antibody induction. Nat. Med., 2016 advance online publication.
25. Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 (2009), 757–769.
26. Sievers, S.A., Scharf, L., West, A.P. Jr., Bjorkman, P.J., Antibody engineering for increased potency, breadth and half-life. Curr. Opin. HIV AIDS 10 (2015), 151–159.
27. Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S., Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83 (2009), 7337–7348.
28. Sommerstein, R., Flatz, L., Remy, M.M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., Ter Meulen, J., et al. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog., 11, 2015, e1005276.
29. Stephenson, K.E., Barouch, D.H., Broadly Neutralizing Antibodies for HIV Eradication. Curr. HIV/AIDS Rep. 13 (2016), 31–37.
30. Stewart-Jones, G.B., Soto, C., Lemmin, T., Chuang, G.Y., Druz, A., Kong, R., Thomas, P.V., Wagh, K., Zhou, T., Behrens, A.J., et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell 165 (2016), 813–826.
31. Szakonyi, G., Klein, M.G., Hannan, J.P., Young, K.A., Ma, R.Z., Asokan, R., Holers, V.M., Chen, X.S., Structure of the Epstein-Barr virus major envelope glycoprotein. Nat. Struct. Mol. Biol. 13 (2006), 996–1001.
32. Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003), 307–312.
33. Wibmer, C.K., Bhiman, J.N., Gray, E.S., Tumba, N., Abdool Karim, S.S., Williamson, C., Morris, L., Moore, P.L., Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog., 9, 2013, e1003738.
34. Wu, X., Wang, C., O'Dell, S., Li, Y., Keele, B.F., Yang, Z., Imamichi, H., Doria-Rose, N., Hoxie, J.A., Connors, M., et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J. Virol. 86 (2012), 5844–5856.
35. Wu, X., Zhang, Z., Schramm, C.A., Joyce, M.G., Kwon, Y.D., Zhou, T., Sheng, Z., Zhang, B., O'Dell, S., McKee, K., et al., NISC Comparative Sequencing Program. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell 161 (2015), 470–485.
36. Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I.S., Altae-Tran, H.R., Chuang, G.Y., Joyce, M.G., et al., NISC Comparative Sequencing Program. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39 (2013), 245–258.
37. Zhou, T., Lynch, R.M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N.A., Joyce, M.G., Lingwood, D., Soto, C., Bailer, R.T., et al., NISC Comparative Sequencing Program. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell 161 (2015), 1280–1292.
38. Zlateva, K.T., Lemey, P., Vandamme, A.M., Van Ranst, M., Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. J. Virol. 78 (2004), 4675–4683.